Add Yahoo as a preferred source to see more of our stories on Google. A cure for the herpes simplex virus could be on the horizon after researchers at the Fred Hutch Cancer Center in Seattle say ...

Detailed price information for Theralase Technologies Inc. (TLT-X) from The Globe and Mail including charting and trades.

Theralase® validates previous University of Manitoba research by demonstrating that RuvidarTM is safe and effective in the treatment of the Herpes Simplex Virus in an animal model. TORONTO, ON / ...

Ruvidar(TM) demonstrates higher efficacy in the treatment of Herpes Simplex Virus, Type 1 versus FDA-approved, standard of care treatments Acyclovir and Abreva in a preclinical animal model. In the ...

Ruvidar(TM) demonstrates higher efficacy in the treatment of Herpes Simplex Virus, Type 1 versus the standard of care treatments Acyclovir and Abreva in a preclinical animal model. Toronto, ...

SEATTLE — May 13, 2024 — Researchers at Fred Hutch Cancer Center have found in pre-clinical studies that an experimental gene therapy for genital and oral herpes removed 90% or more of the infection ...

Assembly Biosciences, Inc. (NASDAQ:ASMB) released interim pharmacokinetic (PK) and safety results from healthy participants in the Phase 1a portion of its ongoing Phase 1a/b study of ABI-5366, an ...

Herpes is shockingly common. Recent estimates suggest at least half of all Americans have HSV-1, or oral herpes, which usually manifests as cold sores on or around one’s mouth, but can spread to ...

If you have ever experienced a cold sore, you may be one of the estimated 3.8 billion people worldwide (64%) who are infected with herpes simplex virus type 1 (HSV-1). Though the majority of people ...